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Abstract There is an urgent need to develop new methods for male contraception, however a
major barrier to drug discovery has been the lack of validated targets and the absence of an
effective high-throughput phenotypic screening system. To address this deficit, we developed a
fully-automated robotic screening platform that provided quantitative evaluation of compound
activity against two key attributes of human sperm function: motility and acrosome reaction. In
order to accelerate contraceptive development, we screened the comprehensive collection of
12,000 molecules that make up the ReFRAME repurposing library, comprising nearly all the small
molecules that have been approved or have undergone clinical development, or have significant
preclinical profiling. We identified several compounds that potently inhibit motility representing
either novel drug candidates or routes to target identification. This platform will now allow for
major drug discovery programmes that address the critical gap in the contraceptive portfolio as
well as uncover novel human sperm biology.
Introduction
An effective and comprehensive family planning strategy is fundamental to delivery on the United
Nations 17 Sustainable Development Goals (Starbird et al., 2016; Goodkind et al., 2018), however
the current contraceptive portfolio is suboptimal. For example, it is estimated that more than 214
million women in developing countries have an unmet need for contraception which results in 89 mil-
lion unintended pregnancies and 48 million abortions every year, with substantial impacts on mater-
nal and child health and poverty levels (Guttmacher Institute, 2017). To achieve the UN targets it is
critical that involvement of men be considered of equal importance as women (Hardee et al., 2016).
However, it is noticeable that no effective, reversible and widely available form of contraception has
been developed for men since the condom and as such the burden falls largely on the woman. The
development of drugs that can be used in the male would address a critical gap in the contraceptive
portfolio.
Progress in developing new male contraceptives has been slow for a plethora of reasons. Despite
decades of research, safe and effective hormonal approaches to prevent spermatozoa production
have yet to be realised and viable alternatives remain elusive (Page and Amory, 2018). Developing
a drug for any purpose is difficult but one that blocks sperm function is a particular challenge as
spermatozoa don’t divide, transcribe or translate, have specialized organelles, are highly motile and
continually produced in large numbers (~100 million per day). Moreover, as the production of fertili-
zation competent cells is necessarily different between species, it is essential to use a human system
early in the drug discovery cascade to increase the chances of translational success. The spermato-
zoa’s sole function post-ejaculation is to swim until it closes in on the oocyte. The spermatozoa are
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then able to undergo a unique exocytotic process called the acrosome reaction (AR) which facilitates
penetration of the zona pellucida, the oocyte’s outer glycoprotein shell and allows fusion with the
oocyte’s plasma membrane, delivering its DNA. Hence, a male contraceptive could work in a num-
ber of different ways – it could completely halt spermatogenesis, block an essential function of the
spermatozoon (such a motility) or perturb a cellular process that results in a non-productive interac-
tion with the oocyte (such as prematurely triggering the acrosome reaction, and/or by blocking exo-
cytosis or inhibiting receptor binding). Low sperm motility is a common cause of male infertility
(Samplaski et al., 2019) indicating that targeting this process should yield effective drugs. The
options for delivery of a contraceptive are wide ranging, but our primary aim is to develop a rela-
tively fast-acting safe drug, self-administered by the male, that specifically and effectively irreversibly
blocks the sperm’s ability to get to the egg and/or fertilise it.
Though some potential sperm-specific contraceptive drug targets, such as the calcium channel
CatSper, have been identified (Lishko and Mannowetz, 2018), our relatively poor understanding of
spermatozoon biology makes target-agnostic, or phenotypic strategies more attractive
(Barratt et al., 2017). Phenotypic drug discovery is undergoing a renaissance in a number of thera-
peutic areas because it can uncover novel biology in an unbiased way. Retrospective analysis of drug
approvals shows the approach to be more successful in first-in-class medicine discovery than previ-
ously appreciated (Swinney and Anthony, 2011; Moffat et al., 2017). However, for male con-
traceptive drug discovery, a limiting barrier has been the absence of a scalable drug screening
system using spermatozoa.
To address this unmet need we set out to develop the first high-throughput phenotypic screening
platform for sperm where an imaging-based kinetic analysis module that tracks motility, is followed
by a flow cytometry -based assay module that detects both the degree of acrosome reaction (AR)
and cell viability - both modules coordinated by a fully automated robotic system. The bespoke
computational pipeline quantitatively evaluates each compound’s effect on both motility and AR
(and viability) thus achieving unprecedented throughput. The platform was used to identify motility
inhibitors from a unique 12,000 molecule ReFRAME (Repurposing, Focused Rescue, and Accelerated
Medchem) library, which represents the most comprehensive collection of drugs available, as it con-
tains nearly all the small molecules that have achieved regulatory approval and others that have
undergone varying degrees of clinical development or have had significant preclinical profiling
(Janes et al., 2018). This advance opens up the possibility of accelerated male contraceptive devel-
opment by allowing drug repurposing, target identification as well as screening of chemical diversity
libraries for novel medicinal chemistry start points.
Results
Phenotypic assay development
Our automated platform (Figure 1A) allows for the identification of relatively fast-acting compounds
with a rapid plate-processing time (~75 minutes/ 384-well plate), where the motility assay runs
for ~30 min followed directly by the AR assay (~45 min). Automated cell tracking (Figure 1B and Fig-
ure 1—figure supplement 1A,B) using time-lapse images allowed kinetic parameter quantification
on >200 cells/well (Figure 1C). The kinetics show good agreement with clinical systems (Figure 1—
figure supplement 1C) and a comparable distribution was observed between experimental days,
plates and positions (Figure 1—figure supplement 2) with any small differences between days
stemming from donor pool variance. Importantly, spermatozoa were found to be tolerant to the
DMSO concentrations used in our screening program (0.0625%–0.1% Figure 1—figure supplement
1D). To determine the optimal screening batch size untreated spermatozoa were dispensed every
30 min for 150 min observing only a small decrease in motility (~10%) after four plates were screened
(Figure 1—figure supplement 1E). A flow cytometry-based assay measuring AR (Figure 1D) was
run directly afterwards (Figure 1E and Figure 1—figure supplement 1F).
Screening of the ReFRAME library, confirmation of hits by dose
response
The ReFRAME library (11,968 compounds) was supplied in ‘assay-ready’ imaging plates and was
solubilised prior to addition of sperm. High assay quality was achieved throughout with a Z’-factor
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Figure 1. Phenotypic Assay workflows. (A) Graphical summary of modular screening workflow where motility measurement is followed by acrosome
reaction (AR) measurement allowing a screening throughput of >1400 compounds per donor pool (B) Steps in imaging and analysis: human sperm are
recorded with brightfield illumination (first panel) then sperm heads detected using a particle tracking algorithm (second panel) which are then tracked
across the timelapse series of images (third panel) and subsequently classified (fourth panel). Each panel contains a zoomed-in subsection of the field.
Colour coding for tracking distance and kinetic classification is shown in the panel insets: Tracking panel - rainbow gradient (showing progression over
time); Classification panel - red for immotile (IM), yellow for non-progressively motile (NPM) and blue for progressively motile (PM). Scale bars: 100 mm
(main images), 5 mm (insets). (C) Sperm counts per well after microscopy and detection shown in a combined violin/box plot. Colours: purple violin
outline (probability density of values), yellow dots (outliers of boxplot). (D) Graphical summary of the expected populations determined by flow
cytometry based on distribution of cells measured with FL3-A (Pi) vertical axis and FL1-A (PNA-488) horizontal axis: dead cells (upper left, Pi+ PNA-);
dead and acrosome-reacted (upper right, Pi+ PNA+); unstained/live/non-reacted (lower left) and live acrosome-reacted (lower right, Pi-PNA+). (E)
Example flow cytometry data comparing sperm treated with the Ca2+ ionophore (A23187) which induces AR (left panel) with sperm from DMSO-treated
well (right panel). Colours indicate event density. (F) Combined violin/box plot data showing flow cytometry event counts per well. Colours and label as
in (C).
The online version of this article includes the following figure supplement(s) for figure 1:
Figure 1 continued on next page
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between 0.4–0.8 (Figure 2B). A total of 63 putative hit compounds decreased motility to varying
degrees based on a hit selection cut-off of >15% reduction in motility (Figure 2A with examples in
Figure 2C,D,F,G and Video 1 and 2). 14 compounds were selected as putative AR+ hits (Figure 3A
with examples in B, C). Motility hits were confirmed with resupplied material in dose-response
experiments. There was a dose-dependent decrease in motility for 29 compounds (46% hit confirma-
tion rate), with EC50 values as low as 0.05 mM and effect sizes ranging from 15–100% (Figure 2F,G;
Figure 2—source data 1, Supplementary file 1). Amongst the confirmed hits were the aldehyde
dehydrogenase inhibitor, Disulfiram (70% maximum reduction at 10 mM) and a putative platelet
aggregation inhibitor, KF-4939 (100% max. reduction; EC50 = 0.49 mM), and a range of other com-
pounds having very modest effect and/or showing low potency (See Figure 2—source data 1,
Supplementary file 1). In order to test reversibility, wash out experiments were performed. Only a
small recovery of motility was observed, after wash out of Disulfiram (Figure 2—figure supplement
1). In the AR screen, 9 of the resupplied compounds had a dose-dependent effect with EC50 values
as low as 0.4 mM (See Figure 3—source data 2, Supplementary file 2). However, following the
orthogonal assay triaging we implemented to eliminate assay interference compounds, none of the
AR hits were found to be true positives (see examples in Figure 3—figure supplement 1D) despite
the primary screen showing good assay robustness.
Discussion
A major barrier in the search for new male contraceptives has been the lack of an effective high
throughput phenotypic screening system. This study presents the first platform based on imaging
and flow cytometry that measures two fundamental aspects of sperm behaviour – motility and AR,
allowing for the rapid screening of compound collections.
A significant challenge was to create a system for the tracking of these highly motile cells that
was fully automated and scalable to allow throughput at sufficient speed. Moreover, concomitant
assessment of a second functional attribute, AR along with cell viability was developed in order to
maximise use of the biological material. Assessment of motility required novel implementation of
tracking algorithms. Importantly, the kinetic outputs were equivalent to those from the ‘industry-
standard’ CASA, which is very low throughput and unsuitable for screening more than a few com-
pounds at one time. Significant workflow optimisation resulted in good assay robustness and an
acceptable hit confirmation rate following the primary screen using a medium stringency cut off for
hit selection (>15% reduction). For AR detection, a flow cytometry approach was taken based on
established methods (Mortimer et al., 1987) and showed good assay robustness. However, the
presence of assay-interfering compounds in screening libraries (potential fluorescent compounds
including DNA intercalators) necessitated further triaging steps (see Materials and methods) to elimi-
nate false positives. This combination of triaging approaches meant that, in this screen, no AR com-
pounds were suitable for progression. An improvement to the AR primary assay could be to use a
far-red labelled lectin reagent to detect the glycoproteins. Other variants of the assay would be to
either use sperm that had been capacitated, a state of increased readiness to undergo the AR pro-
cess or use it to find drugs that would block the AR induced by a physiological stimulus. These latter
variants are worthy of future investigation.
It is worth noting that whilst the primary goal of this programme is to identify compounds that
will act as contraceptive by decreasing motility we detect a larger number of putative motility upre-
gulating hits. These compounds are of interest for not only target identification and uncovering
novel sperm biology but also their potential to improve fertility treatments. Overall, although the
two assays presented here are fairly complex biological assay using primary cells, it achieved accept-
able throughput with the potential to increase batch size for larger screening campaigns.
The advantage of using the ReFRAME collection was the potential to repurpose drugs that are
already approved for other indications, or are at earlier stages of clinical progression. The associated
Figure 1 continued
Figure supplement 1. Further characterisation of phenotypic assays.
Figure supplement 2. Screening consistency over time analysis.
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Figure 2. ReFRAME Library Screening: Motility Assay Results. (A) Primary screening results of the motility assay. Each dot represents a well (either
compound or control well) showing % of DMSO control (Curvilinear Velocity: VCL). Positive controls (Pristimerin), negative controls (DMSO) and
individual compound datapoints are shown. The dashed line showing the 15% of control (reduction in VCL) – the cut-off for primary hit selection. Total
number of compounds = 11,903, excluding wells with auto-focus errors and with ‘sticky’ compounds which have been excluded from analysis.
See dataset (http://doi.org/10.5061/dryad.jdfn2z36z) Figure 2—source code 1. (B) Assay robustness: the standard high throughput screening metric, Z’
(see Materials and methods; Zhang et al., 1999) was used to determine the performance of the assay for all screening plates. Dashed lines indicate
min/max Z’ values. (C) Tracking data visualizations of 3 example wells showing sperm tracks of both imaging positions (Position 1 [Pos. 1] and Position 2
[Pos. 2] respectively) within the wells. A DMSO control well (left panels ‘Control’) shows a large number of progressively motile (PM) sperm (yellow) with
few non-progressively motile (NPM) sperm (green and very few immotile (IM) sperm (purple) – this is in contrast to the shorter tracks and higher levels
of NPM and IM in the middle panel (‘20% reduction’) for a compound that shows 20% inhibition of motility (i.e. 80% of control) and the right hand panel
(‘80% reduction’) for a compound showing 80% inhibition (i.e. 20% of control), showing almost all cells are in the IM and NPM classes. (D) Histogram of
sperm tracks quantification of the data show in (C). (E) Summary of motility assay hit rate (0.5%) and reconfirmation rate (0.24%). (F-G) Dose response
confirmation of two hits. 8-point 3-fold dilution curves are shown with 10 mM as the highest concentration. Two data points per concentration (n = 2,
data point is mean ± SD). Each curve is a 4-parameter logistic fit. Each plot shows estimated values Hill Slope and EC50. The chemical structure of the
hit compound is shown as well as some annotation and physicochemical properties. Physicochemical properties were calculated using RDKit, Python
and KNIME: SlogP = partition coefficient (Wildman and Crippen, 1999); TPSA is the Topological Polar Surface Area (Ertl et al., 2000); MW is the
exact Molecular weight; QED = Quantitative Estimate of Drug-likeness (Bickerton et al., 2012).
The online version of this article includes the following source data, source code and figure supplement(s) for figure 2:
Source code 1. R Code for Figure 2 primary motility assay.
Figure 2 continued on next page
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compound annotations and safety data offers the potential to help accelerate the development of
an effective male contraceptive. In the motility assay the hit rate of ~0.2% is typical for a cell-based
assay, however surprisingly a relatively high number of hits were not deemed suitable for compound
progression. Examples included potentially toxic mercury-containing compounds (phenylmercuric
borate and mercufenol chloride); antiseptics and antibiotics including tyrothricin, or compounds with
impacts on fundamental biology for example the microtubule stabiliser and chemotherapeutic, doce-
taxel. However, several hits are potentially of interest. One is Disulfiram (70% reduction at 10 mM) a
drug that is well tolerated, has long been used for treating alcohol dependency and has previously
been shown to inhibit sperm motility (Lal et al., 2016). Disulfiram is unlikely to be developable as a
suitable contraceptive drug due to its side-effects when alcohol is consumed but has potential to
facilitate mode-of-action studies. One recent report identified 3-Phosphoglycerate dehydrogenase
(PHGDH) as a target for disulfiram (Spillier et al., 2019) whilst another identified NLP4, a subunit of
VCP/p97 segregase (Skrott et al., 2017; Skrott et al., 2019) although the relevance of either to
sperm function is unclear. The identification of KF-4939, a putative platelet aggregation factor (PAF)
inhibitor, as a potent hit (100% max. reduction EC50 = 0.5 mM) may also be of interest since PAF has
been used to improve sperm function in male infertility treatments (Roudebush et al., 2004). It is
noteworthy that like disulfiram, KF-4939 also contains a disulphide linkage indicating that its biologi-
cal effect maybe mediated by modifying sulfhydryls on proteins (Yamada et al., 1985). Further thiol-
containing compounds, bismuth ethanedithiol (98% max reduction; EC50 = 2.5 mM) and the anti-fun-
gal benzothiazole, Ticlatone (96% max. reduction EC50 = 4.4 mM) were also potent hits, suggesting
free cysteines in, as yet, unidentified protein(s), may play a critical role in motility. Of interest is the
observation that the Toll-like receptor 7/8 ligand (Resquimod; R848), recently shown to preferentially
reduce the motility of X chromosome-bearing mouse sperm by suppressing ATP production
(Umehara et al., 2019), was a hit, demonstrating that this phenotypic screening approach has the
potential to uncover new aspects of sperm biology.
It was somewhat surprising that relatively few drugs or drug-like molecules in the ReFRAME col-
lection were potent and effective inhibitors in the motility assay. This may reflect the unique biology
of the spermatozoon that has evolved for a singular purpose – to reach the oocyte and fertilise it
and/or that the targets within pharma’s therapeutic areas of interest over the last few decades are
not similarly functional in human sperm. Conversely however, we did observe a large number of
compounds (Figure 2A) that had a significant positive effect on sperm motility which may be target
agonists as well as potential start points for
Figure 2 continued
Source code 2. R Code for Figure 2—source data 1 dose response confirmation motility assay.
Source data 1. Dose response and additional data for primary motility hits.
Source data 2. Dose response confirmation data motility assay.
Figure supplement 1. Disulfiram Washout CASA measurement of percentage total motility in samples: prior to treatment (Squares); 20 mins after
treatment with DMSO (triangles) or 10 mM disulfiram (circles); 60 min after washout of compound/DMSO.
Figure supplement 1—source code 1. R code for Figure 2—figure supplement 1 Disulfiram washout assay.
Figure supplement 1—source data 1. Disulfiram washout data.
Video 1. Movie was generated using a brightfield
image sequence for a typical control well (left pane), a
well where a compound reduced motility by 20%
(middle pane) and one where it reduced it by 80%
(right pane).
https://elifesciences.org/articles/51739#video1
Video 2. Movie was generated using a brightfield
image sequence for a typical control well (left pane), a
well where a compound reduced motility by 20%
(middle pane) and one where it reduced it by 80%
(right pane). Tracking is overlayed in each panel.
Colour coding is detailed in Figure 2.
https://elifesciences.org/articles/51739#video2
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treating men with low sperm motility. The development of an effective safe male contraceptive is
challenging because a prerequisite, other than the obvious need for safety, is a level of reversibility.
Other possibilities, such as a drug taken by the female or an agent for use as a topical spermicide
(for example to replace nonoxynol-9) are options to consider in the future and depend to a large
extent on the pharmacokinetic properties of compounds we identify and their mode of action – for
example some may have poor bioavailability.
In summary, our high-throughput phenotypic platform allows for the screening of bioactives
including natural products, focussed small molecule libraries and chemical diversity sets, which can
provide novel start-points for male contraceptive drug development, as well as the identification of
new drug targets in human spermatozoa.
Materials and methods
Key resources table
Reagent type
(species) or resource Designation Source or reference Identifiers
Additional
information
Biological sample
(Homo sapien)
Live spermatozoa Donated semen
samples
Local ethical
approval (13/ES/0091)
Antibody Lectin PNA
(Arachis hypogaea),
Alexa Fluor 448 Conjugate
ThermoFisher
Scientific
ThermoFisher:L21409;
RRID: AB_2315178
Stored as 1 mg/mL
stock in DMSO; used
at 1:1000 final dilution
Commercial
assay or kit
Propidium Iodide;
Live/Dead Sperm
Viability kit,
ThermoFisher
Scientific
ThermoFisher:L7011, Stored as 2.4 mM stock;
used at a 1:2000 final dilution
Chemical
compound, drug
ReFRAME
(Repurposing,
Focused Rescue,
and Accelerated
Medchem) library
CALIBR at the
Scripps Institute;
Publication
(Janes et al., 2018)
www.reframedb.org
Chemical
compound, drug
Pristimerin Merck Merck:530070 Stored as 10 mM
stock in DMSO;
used at final
concentration of 20 mM
Chemical
compound, drug
calcium ionophore (A23187) Sigma-Aldrich Sigma-Aldrich:C7522 Stored as 10 mM stock
in DMSO, used at a final
concentration of 10 mM)
Chemical
compound, drug
Disulfiram Tocris Tocris:3807 Stored as 10 mM stock
in DMSO, used at
10 mM final concentration
Software,
algorithm
Trackpy v0.4.1 Zenodo.
(http://doi.org/
10.5281/zenodo.1226458)
Publication:
(Crocker and Grier, 1996);
Publication:
(Allan, 2018)
Software,
algorithm
FFMPEG FFmpeg Developers
(http://ffmpeg.org)
RRID:SCR_016075
Software,
algorithm
Bioconductor
packages
Bioconductor
(https://bioconductor.org)
RRID:SCR_006442 flowCore,
flowDensity,
flowWorkspace, ggcyto
Software,
algorithm
HDF5 HDF Group
(www.hdfgroup.org)
Software,
algorithm
dr4pl Dr4pl
(https://cran.r-project.org/web/packages
/dr4pl/index.html)
Software,
algorithm
Code used for
data analysis
This paper The R code used for data
analysis is included
in the
supplement files
accompanying this paper
Continued on next page
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Continued
Reagent type
(species) or resource Designation Source or reference Identifiers
Additional
information
Software,
algorithm
KNIME Berthold et al., 2008 https://www.knime.com
Software,
algorithm
RDKit RDKit, 2018 https://www.rdkit.org
Ethical approval
Written consent was obtained from each donor in accordance with the Human Fertilization and
Embryology Authority (HFEA) Code of Practice (version 8) under local ethical approval (13/ES/0091)
from the Tayside Committee of Medical Research Ethics B.
Development of methods for motility and Acrosome Reaction (AR)
A pre-existing automated cell-based phenotypic screening platform was adapted with the use of live
human spermatozoa. The platform utilises a Yokogawa CV7000 Cell Voyager high-throughput micro-
scope able to image 384 multiwell plates under full environmental control acquiring timelapse
images at a sufficiently high speed (~48 fps)_to capture the fast-moving sperm for tracking analysis.
For high throughput screening with human spermatozoa to be effective and yield meaningful hits,
the system needed to replicate, as close as possible, the manual workflow currently used in an
DMSO
B
65 % Pi- PNA+
C
15% hit cuf-o
Panel C
A
D Acrosome assay results:
14 primary hits with > 15 % induction
9 hits conrmed
dose response curve
Further follow-up Fluorescent assay
interfering compound (9 hits)
Orthogonal assays:
-Plate reader
-Flow cytometer (no stains added)
-Manual Microscopy
-Cheminformatics (Web search, KNIME)
no yes
Figure 3. ReFRAME library screening: ar assay results. (A) Results of primary screening of the library using the acrosome assay (live cells, acrosome
reacting, Pi- PNA+ population). Each dot represents a well (either compound or control well). Shown is % Events (number of events in Pi- PNA+ gate
relative to total events in the sampled well). Datapoints for compounds, negative controls (DMSO) and positive controls (A23187) are shown. Black
dashed line = 15% threshold for primary hits selection. See Figure 3—source data 1 along with Figure 3—source code 1. (B-C) Data from two
example wells: a DMSO well (left panel) and a well with 65% Pi- PNA+ population (right panel). (D) Summary of acrosome assay results before and after
triage.
The online version of this article includes the following source data, source code and figure supplement(s) for figure 3:
Source code 1. R Code for Figure 2 primary acrosome assay.
Source code 2. R Code for Figure 3—source data 2 dose response confirmation acrosome assay.
Source data 1. Primary screening data acrosome assay.
Source data 2. Dose response and additional data for primary AR hits.
Source data 3. Dose response confirmation data acrosome assay.
Figure supplement 1. Further analysis of AR screening data and triaging strategy.
Gruber et al. eLife 2020;9:e51739. DOI: https://doi.org/10.7554/eLife.51739 8 of 14
Short report Developmental Biology
andrology lab, so that the effect of large numbers of compounds on viable human sperm could be
performed. In order to achieve this goal, we investigated a number of factors that could impact the
quality of the data such as: plate type; concentration and number of spermatozoa per well; logistics
of spermatozoa preparation by density gradient centrifugation and handling; donor-pooling; dis-
pense speed for getting spermatozoa into 384 well plates; timing of compound addition; tempera-
ture control; image acquisition parameters; algorithm choice for motility assessment and data
management and, evaluating the overall speed of data analysis. In addition, a flow cytometry-based
assay and data analysis workflow was developed to measure acrosomal status and cell viability. We
chose to perform all experiments on non-capacitated sperm as this condition is the most consistent,
less prone to donor-effects and is closer to the state in which the sperm will be when they would be
encountering the male contraceptive drug. The goal was to be able to screen a 384-well plate in
both assays consecutively within 90 min of sperm dispensing using the fully automatic robotic sys-
tem. Data was analysed for inter- and intra-plate variation (both technical and biological replicates)
and signal-to-background and variance measured to demonstrate the assay was reproducible and
robust. The assay was shown to be scalable and all the workflows optimal. Once established, the sys-
tem was validated by screening the ReFRAME library (Janes et al., 2018) and hits confirmed by
dose-response analysis.
Sperm handling
Control semen samples were obtained from volunteer donors with normal sperm concentration,
motility and semen characteristics (WHO, 2010) and no known fertility problems. Samples were
obtained by masturbation after 48–72 hr of sexual abstinence. After ~ 30 min of liquefaction at 37˚C,
cells were prepared using a discontinuous density gradient procedure (DGC). Semen was loaded on
top of a 40–80% suspension of Percoll (Sigma Aldrich, UK) diluted with non-capacitation medium
using Minimal Essential Medium Eagle, supplemented with HEPES, Sodium lactate and Sodium Pyru-
vate to achieve a similar buffer as described previously (Tardif et al., 2014). We routinely pooled
samples after DGC from 3 to 5 donors for use in each screening batch run in order to reduce donor-
to-donor variability. Samples were obtained and analysed in line with suggested guidance for human
semen studies where appropriate (Bjo¨rndahl et al., 2016).
Motility assay
Sperm cells were incubated for 3 hr at 37˚C after DGC, transferred to the robotic platform (HighRes
Biosolutions Inc) and maintained at 37˚C with gentle stirring (100 rpm) in a water bath on top of a
magnetic stirrer. Approximately 10,000 spermatozoa (10 ml) were dispensed per well using a Multi-
Drop Combi (ThermoFisher) into pre-warmed assay-ready plates. Spermatozoa were incubated with
the compounds for 10 mins (thus favouring fast acting compounds) at 37˚C in the CV7000 micro-
scope prior to the commencement of imaging.
Time-lapse imaging
A CV7000 Cell Voyager high-content imaging system (Yokogawa) was used as it allowed full environ-
mental control, sufficient contrast using simple brightfield optics and a fast acquisition rate (up to 45
frames per second). Using a 20x lens with bright field illumination (0.11 ms exposure, 3% lamp
power), time-lapse image series were acquired (24 frame in 0.5 s) at two positions per well (with a
400 mm gap between positions to eliminate double counting of sperm). Image acquisition across a
384-well plate with such settings takes ~ 17 min.
Sperm tracking
A Python implementation of the particle tracking algorithm originally developed by others
(Crocker and Grier, 1996) was employed (Trackpy v0.4.1 Allan, 2018). The algorithm determines
the position of every sperm head in each frame and links the position over time creating tracks. We
optimized the algorithm parameters for our imaging data to exclude sperm cross-tracks and avoid
detecting non-sperm particles. The image data (~17,000 files amounting to 21 GB per plate) can be
processed within 30 min using a standard desktop PC (Intel Core i5-6600 CPU, 3.3 GHz, 8 Gb RAM)
and can also be parallelized on a compute cluster with minimal effort.
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Acrosome assay
A flow cytometry-based assay was developed employing an iQue Screener (Sartorius) with
Alexa488-conjugated peanut agglutinin (PNA) (Mortimer et al., 1987) and general sperm viability
(using propidium iodide, Pi). This assay was run directly after motility assessment. Controls (DMSO
and the Ca2+ ionophore A23187) were added using an acoustic dispenser (Echo 555, Labcyte Inc)
and incubated for 10 min at 37˚C in the SteriStore (HighRes Biosolutions Inc). PNA488 (ThermoFisher
Scientific, Cat. No. L21409, stored as 1 mg/mL stock) was then added to achieve a 1:1000 final dilu-
tion and propidium iodide (ThermoFisher Scientific, Live/Dead Sperm Viability kit, Cat. No. L7011,
stored as 2.4 mM solution) was added to achieve a 1:2000 final dilution using a liquid handler (Tem-
pest, Formulatrix). After addition of dyes, plates were incubated for 10 min at 37˚C in the SteriStore
before sampling using an iQue Screener (2 s sip time per well with pump setting of 45 rpm). This
resulted in a sample processing time of about 25 min per 384-well plate. Cells were categorised as
either: unstained cells; ‘dead’ cells (Pi+ PNA-); Acrosome-reacted but ‘dead’ cells (Pi+ PNA+); or
Acrosome-reacted ‘live’ cells (Pi- PNA+). This method is capable of detecting a shift of populations
(Pi+ and PNA+) upon induction of AR using A23187. The AR assay was performed as an agonist
screen (scoring for induction of AR in live cells compared to DMSO controls) with the expectation
that compounds could be found that induce AR beyond levels of induction with A23187.
Controls and QC criteria
For the motility assay DMSO was used as a vehicle control (negative control) and Pristimerin (Merck,
Cat. No. 530070, stored as 10 mM stock in DMSO; final concentration of 20 mM) as a positive con-
trol. For the acrosome assay we added a calcium ionophore (A23187, Sigma-Aldrich, Cat. No.
C7522, stored as 10 mM stock in DMSO, used at a final concentration of 10 mM) as a positive control
and DMSO was added to wells as a negative control to be at the same final concentration as that
present in the compound-containing wells (0.0625%). DMSO tolerance was tested by performing the
standard motility assay exposing sperm to increasing concentrations (max 10%) of DMSO for 10 min.
We calculate the standard statistical measure of assay robustness, the Z’ value (Zhang et al., 1999)
for each plate using positive and negative controls for the motility assay and observed Z’ values
ranging between 0.4–0.8. In addition, we performed a visual check of heatmaps for every plate to
detect edge effects.
Data analysis and normalization
Motility
custom R scripts were written to calculate standard sperm kinetic parameters (Mortimer et al.,
2015). Those parameters allow classification of sperm into standard WHO classes: progressively
motile (PM) (where average path velocity: VAP > 25 um/sec AND straightness: STR > 80%); non-pro-
gressively motile (NPM) (where VAP > 5 um/sec OR straight line velocity: VSL > 11 um/sec), and
immotile (IM). In addition to calculating kinetic parameters, we established a workflow to generate
movies of time-lapse videos with overlapping sperm tracks using R and FFMPEG (FFmpeg Develop-
ers. Available from http://ffmpeg.org). We expressed results as % of control curvilinear velocity:
VCL. This was defined as VCL_median (cpd)/VCL_median(DMSO)*100. Hit selection criteria was 15%
reduction of VCL. VCL was chosen as the main kinetic measurement as it had an acceptable Z’ value
and is independent of path averaging. Wells with autofocus errors or compounds which did not dis-
solve properly (resulting in sperm cells being stuck in one location but moving normally in the rest of
the well) were excluded from analysis.
Acrosome
iQue Screener Data was exported as FCS format and processed using the following Bioconductor
packages for analysing flow cytometry data: flowCore, flowDensity, flowWorkspace, ggcyto (see
https://bioconductor.org). These packages allow handling flow cytometry data as objects, which can
then be compensated, gated and visualized efficiently. In addition, we use HDF5 format (www.
hdfgroup.org) for storing processed and averaged data. Percent events for each population (Pi+
PNA+, Pi- PNA+, Pi+ PNA- and Pi- PNA-), normalized to total well events, were calculated. Hits
were defined as compounds which induce AR beyond 15% (maximum level of induction achieved
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with positive control). Wells with irregularities (low in Pi+ or Pi+PNA+ population, or below 200
events) have been excluded from analysis.
Compound screening
We screened the ~12,000 compound ReFRAME (Repurposing, Focused Rescue, and Accelerated
Medchem) library (Janes et al., 2018; and www.reframedb.org) supplied by CALIBR at the Scripps
Institute. This unique library consists of bioactives and approved drugs that have been assembled
from the literature, drug databases and by patent mining. Compounds dissolved in DMSO were
spotted (12.5 nL, final assay concentration ~ 6 mM) into 384-well black-sided optical imaging plates
(CellCarrier, PerkinElmer) at CALIBR and were shipped on dry ice to the screening centre in Dundee
and stored at  20 ˚C until required. Immediately prior to screening plates were thawed, controls
were added using the acoustic dispenser (Echo 555, Labcyte), and 10 ml warm media added followed
by shaking on a plate shaker for 10 s. Plates were then incubated for 30 min at 37˚C to solubilise the
compounds and prewarm the plates prior to the addition of live sperm (see above). With the addi-
tion of the media containing sperm (10 ml) the final concentration of DMSO in each well was
0.0625%.
All experiments were performed with pools of donors (3–5 per batch of 4 screening plates) and
results normalised to DMSO-treated wells (16 wells per plate). Sperm was first prepared by DGC
and then pooled. Where a single donor sample was found to less than 1/3 of the yield required then
the contribution from the other doors was increased to compensate.
The ReFrame library has been screened for cytotox (using CellTiterGlo) in HEK293 and HepG2
cells (see www.reframedb.org) with some of the hit compounds displaying activity in one or both
assays (Figure 2—source data 1), information which helps inform compound progression decisions.
Dose response experiments
Assay-ready 384-well CellCarrier plates with 8-point curves (10 mM highest concentration) were
resupplied by CALIBR in duplicate and processed as described above. Curves were fitted using the
R package dr4pl (https://cran.r-project.org/web/packages/dr4pl/index.html) using a 4-parameter
logistic fit option.
Triaging of AR hits
Given the prevalence of a range of interfering compounds amongst the library hits, two approaches
were used for triaging. These additional triaging steps, after the primary screen, allowed for the
elimination of intrinsically fluorescent compounds and compounds fluorescing in the presence of bio-
logical material. Screening plates were excited at 488 nm and read at 520 nm and 670 nm in a
M1000Pro multimode plate reader (Tecan) after flow cytometry. In addition, when performing dose-
response curve follow up on resupply material a replicate set of compound-dosed cells were proc-
essed with no-dyes added. This identified the small number of compounds whose fluorescence is
indistinguishable from a true positive. In addition, visual confirmation of the appropriate pattern of
acrosome staining was performed by microscopy.
Disulfiram washout assay
In order to assess the ability of sperm cells to recover motility after Disulfiram removal, wash-out
experiments were conducted at two timepoints using non-capacitating conditions. Spermatozoa
were pooled after DGC preparation in the same manner as for screening. Pooled samples were
diluted to a concentration of approximately 106/mL and incubated at 37˚C under non-capacitating
conditions (see above). After this initial incubation period, Disulfiram (10 mM final concentration) or
vehicle control (DMSO to 0.1% final concentration) were added and incubated at 37˚C for 20 min.
Following exposure to Disulfiram or DMSO control, sperm cells were washed by centrifugation at
300 g for 5 min in 5 mL of the non-capacitation media. After washing, the pellet was resuspended in
500 ml of the appropriate media and incubated at 37˚C for 1 hr. Samples were taken for analysis by
computer-assisted-sperm analysis (CASA) [CEROS machine (version 12), Hamilton Thorne Research,
Beverly, MA, USA] before treatment, after 20 mins treatment and 1 hr post washout. Wash-out
experiments were performed on three separated days, utilising different donors to make up the
Gruber et al. eLife 2020;9:e51739. DOI: https://doi.org/10.7554/eLife.51739 11 of 14
Short report Developmental Biology
pooled sample. Each condition was repeated in duplicate on each of these days and each CASA
reading was performed in duplicate.
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